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Abstract: 
Aim: To investigate whether lesions on diffusion-weighted imaging (DWI+) after carotid artery 
stenting (CAS) or endarterectomy (CEA) might provide a surrogate outcome measure for 
procedural stroke. 
Methods: Systematic MedLine® database search with selection of all studies published up to the 
end of 2016 in which DWI scans were obtained before and within 7 days after CAS or CEA. The 
correlation between the underlying log odds of stroke and of DWI+ across all treatment groups 
(i.e. CAS or CEA groups) from included studies was estimated using a bivariate random effects 
logistic regression model. Relative risks of DWI+ and stroke in studies comparing CAS vs. CEA 
were estimated using fixed-effect Mantel-Haenszel models. 
Results: We included data of 4871 CAS and 2099 CEA procedures (85 studies). Across all 
treatment groups (CEA+CAS), the log odds for DWI+ was significantly associated with the log 
odds for clinically manifest stroke (correlation coefficient 0.61 [95% CI 0.27 to 0.87], p=0.0012). 
Across all CAS groups the correlation coefficient was 0.19 (p=0.074). There were too few CEA 
groups to reliably estimate a correlation coefficient in this subset alone. In 19 studies comparing 
CAS vs. CEA the relative risks (95% confidence intervals) of DWI+ and stroke were 3.83 (3.17-
4.63, p<0.00001) and 2.38 (1.44-3.94, p=0.0007), respectively. 
Discussion and Conclusion: These findings strengthen the evidence base for the use of DWI 
as a surrogate outcome measure for procedural stroke in carotid revascularization procedures. 
Further randomised studies comparing treatment effects on DWI lesions and clinical stroke are 
needed to fully establish surrogacy. 
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Introduction 
Atherosclerotic stenosis of the internal carotid artery is a major cause of stroke. Early randomised 
trials demonstrated that carotid endarterectomy (CEA) reduces stroke risk in patients with 
symptomatic and asymptomatic carotid stenosis.1-4 In recent years, carotid angioplasty and 
stenting (CAS) has emerged as an alternative to CEA avoiding general surgical complications and 
morbidity associated with neck incision, as well as shortening hospital stay. In a systematic review 
of 11 randomised trials including 5778 patients with symptomatic carotid stenosis, CAS was 
associated with a higher risk of procedural stroke or death than CEA (8.2% versus 5.0%), although 
the risk difference between CEA and CAS mainly concerned minor strokes which did not lead to 
disability or death and was seen in patients older than 70 years only.5, 6 Conversely, CAS avoided 
cranial nerve palsy and was associated with lower risks of access site hematoma and myocardial 
infarction. Both treatments appear to be equally effective at preventing recurrent stroke after the 
procedural period.7-10  
Further development of surgical and interventional techniques and optimisation of patient 
selection may lead to a reduction in the risk of procedural stroke associated with carotid 
revascularisation. However, phase III trials of new carotid interventions designed to show 
improvement in treatment safety will require many patients and take a long time to complete. For 
example, a clinical trial would require about 2000 patients to detect a true reduction in the risk of 
procedural stroke from 6% to 3% with a new intervention compared to an established intervention, 
at a significance level of 5% and 90% power. The use of a surrogate outcome measure, defined 
as “a variable that provides an indirect measurement of effect in situations where direct 
measurement of clinical effect is not feasible or practical”11 may therefore be justified to investigate 
new interventions in proof-of-concept or phase II studies and inform the decision whether a large 
phase III trial should be initiated.12  
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A large number of small to medium sized studies have reported acute cerebral ischaemic lesions 
on diffusion-weighted magnetic resonance imaging (DWI) to occur in a substantial proportion of 
patients after treatment of carotid stenosis by CAS or CEA (figure 1). Recent review articles 
highlighted the potential of DWI as a surrogate safety outcome measure in clinical trials of carotid 
interventions.13-15. Furthermore, the existing evidence has never been systematically reviewed in 
the context of validating ischaemia on DWI as a surrogate outcome measure for procedural 
ischaemic stroke.  
In general, the strength of evidence for a validated surrogate outcome measure depends on the 
following criteria: Firstly, the biological plausibility of a relationship between the surrogate and the 
clinical outcome measure; secondly, the demonstration of a correlation between the occurrence 
of the surrogate and the clinical outcome measure; and thirdly, evidence from clinical trials that 
the effect of treatment on the surrogate outcome measure (e.g., the relative risk of cerebral 
ischaemia on DWI in CAS vs. CEA) correlates with the treatment effect on the clinical outcome 
measure (e.g., the relative risk of procedural stroke in CAS vs. CEA).11 Based on its specificity to 
image processes in the brain directly linked to cellular hypoxia, and its sensitivity in detecting acute 
cerebral ischaemia,16-18 the use of DWI as a surrogate outcome measure for procedural ischaemic 
stroke seems biologically plausible. In order to explore the second and third criterion for surrogacy, 
we performed a systematic literature review and meta-analysis. We investigated the association 
between the risk of procedural stroke and the risk of cerebral ischaemia on DWI in patients treated 
by CAS or CEA, and compared the effect of CAS versus CEA on the risk of stroke and the risk of 
cerebral ischaemia on DWI.  
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Methods 
Search strategy and study eligibility criteria 
A systematic MedLine® search was conducted to identify all studies investigating patients 
undergoing treatment of carotid artery stenosis by CAS or CEA with DWI, published online with 
access to the full article or in-print version up to December 31st of 2016. The search term (“carotid 
endarterectomy” OR “carotid stenting” OR “carotid angioplasty”) AND (“DWI” OR “diffusion” OR 
“MRI” OR “embolism” OR “ischemia” OR “silent” OR “ischemic lesion” OR “emboli”) was entered 
on http://www.ncbi.nlm.nih.gov/PubMed. We also checked cited studies in retrieved articles and 
existing reviews on MRI in carotid interventions. 13-15, 19   
Studies were included in the analysis if they fulfilled the following criteria: (1) Patients were treated 
for atherosclerotic carotid stenosis (any degree of stenosis, symptomatic or asymptomatic 
stenosis) with either CEA or CAS (with or without use of cerebral protection devices); (2) patients 
were examined with DWI both before and within 7 days after treatment; and (3) the numbers or 
percentages of patients with new lesions on DWI after treatment and procedural ischaemic stroke 
were reported. If several publications resulted from the same cohort of patients, we chose the 
report which included the highest number of patients. Studies assessing brain ischaemia on 
magnetic resonance imaging (MRI) sequences other than DWI were not included. Studies with 
prospective or retrospective design were included as long as they fulfilled the inclusion criteria 
above. Reports on single cases were not included. Likewise, studies reporting on emergency 
procedures (i.e. including intracranial thrombectomy in acute ischemic stroke) were not included. 
Two researchers (CT and LHB) reviewed the abstracts of all publications identified by the search, 
retrieved the full publications where abstract data were consistent with the inclusion criteria, and 
selected the studies for inclusion based on the full published data. 
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Data extraction 
Data was extracted independently by three researchers (LHB, CT and STE). Any disagreement 
was resolved by consensus. For all eligible studies we extracted: the number (N) of included CAS 
or CEA procedures; N patients with symptomatic carotid stenosis, usually defined as ischaemic 
ocular or cerebral symptoms having occurred in the dependent territory of the carotid artery within 
the past 6 months; magnetic field strength (tesla) used in MRI; latency between treatment and 
post-treatment DWI;  N patients with a positive DWI (henceforward referred to as “DWI+”), defined 
as the presence of at least one hyperintense lesion on DWI after treatment which was not present 
on the pre-treatment DWI; and N patients with procedural ischaemic cerebral stroke 
(henceforward referred to as “stroke”), defined as a focal neurological deficit of probable ischaemic 
vascular cause lasting >24 hours occurring up to 30 days after treatment, with exclusion of 
intracranial haemorrhage, hyperperfusion syndrome and other structural brain disease on 
neuroimaging. Pure retinal infarction was not included. Transient ischaemic attack was not 
consistently recorded in the studies and was therefore not extracted.  
For studies involving CAS, we extracted information on whether a cerebral protection device 
(CPD) was used and which type of device. For studies involving CEA, we noted whether a 
standard or eversion technique, a shunt, or a patch was used, and if the procedure was done 
under local or general anaesthesia. For studies including two or more treatment groups (e.g., 
studies comparing CAS vs. CEA or studies comparing CAS with vs. without CPD use), data were 
extracted for each treatment group separately.  
Corresponding authors were contacted via e-mail if the published data was not sufficient to 
determine whether the study was eligible for analysis or not, or to extract the relevant information. 
Additional data obtained in this way (n=5 studies) was also considered in this review.  
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Statistical analysis 
To explore the second criterion for surrogacy, we included all groups of patients treated with CAS 
or CEA from eligible studies for which the proportion or number of patients with DWI+ and 
procedural stroke was reported (henceforth referred to as “treatment groups”) as separate data 
points. First, a crude correlation coefficient for the association between the observed risks of DWI+ 
and the observed risks of stroke was calculated across treatment groups. This correlation 
underestimates the extent of the association between the underlying risks because the 
imprecision in the observed risks dilutes the association as it does whenever an association is 
measured between two measurement error-prone variables. To account for this we utilised a 
bivariate random effects logistic regression model to estimate the correlation between the 
underlying log-transformed odds (log odds) of stroke and the underlying log odds of DWI+. A 
detailed description of this model is given in the supplemental methods.  
A number of studies compared two or more different revascularisation procedures with each other. 
Owing to the relatively small size of these studies, the confidence interval surrounding the 
treatment effects with regard to procedural stroke and DWI+ was wide. For these reasons we 
refrained from further exploring any correlation between treatment effects on stroke and DWI+ to 
evaluate the third criterion for surrogacy. Instead, we investigated in a meta-analysis of all studies 
comparing CAS versus CEA, whether the treatment effect for DWI+ pointed in the same direction 
as the treatment effect for procedural stroke (i.e. whether the comparison between CAS and CEA 
using DWI+ as the outcome favoured the same treatment as the comparison using stroke as the 
outcome). Data were aggregated using fixed-effect Mantel-Haenszel models and treatment effects 
calculated as risk ratios with 95% confidence intervals (95% CI), using CAS as the reference 
treatment. We quantified heterogeneity using the I² statistic. Review Manager Software (RevMan, 
version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was 
used.  
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Reporting Standards  
Data presentation and reporting in this manuscript is done according to the reporting standards of 
the PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses. 20, 21 
 
Results 
Included and excluded studies 
As of March 30th 2017, the search yielded 2555 results (figure 3). Full publications were retrieved 
of 164 studies published up to December 31st, 2016. 79 studies were excluded for the following 
reasons: MRI to detect cerebral ischaemia did not include DWI sequences, or DWI was not done 
in all patients (n=15);22-36 no DWI was performed before treatment (n=11);37-47 post-procedural 
DWI was performed more than 7 days after treatment (n=3);48-50 the number of DWI+ patients or 
procedures could not be extracted (n=6);51-56 or information on procedural stroke was lacking or 
patients with procedural stroke were excluded from the analysis (n=6).49, 57-68 One study was 
excluded because the analysis was restricted to patients with available 6 months follow-up who 
constituted less than half of the study population (n=1).69 One study was excluded since only a 
pre-selected groups of patients showing micro-embolic signals in transcranial doppler during CEA 
were included in the final analysis.70 Another study investigating the use of intravascular 
ultrasound for carotid plaque characterization was excluded since the additional device by itself 
may have contributed to the occurrence of DWI+ or stroke.71  A further 28 studies were excluded 
because updated reports from the same cohort including a larger number of patients had 
subsequently been published and included, or because the studies were secondary analyses of 
previously included studies that contained no additional data relevant for the present review.72-99 
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The remaining 85 studies including 6970 carotid revascularisation procedures (CAS: n=4871; 
CEA: n=2099) fulfilled all eligibility criteria and were included in the analysis. Fourteen studies 
investigated DWI lesions in CEA.100-113 One of these studies retrospectively compared 
conventional with flow-control-CEA (i.e. clamping of the common carotid artery, the external 
carotid artery and the superior thyroid artery before dissection of the carotid sheath around the 
internal carotid artery)108. Six studies investigated DWI lesions in CAS without CPD,114-119 one of 
which using a membrane-covered stent.119 38 studies investigated DWI lesions in CAS with CPD 
120-157: one study randomly compared membrane-covered versus bare-metal stents129; one study 
randomly allocated patients to CAS using flow reversal or distal filter protection,150; one study 
randomly assigned to either proximal or distal cerebral protection during CAS145; one study 
compared open vs. closed-cell stent type in a randomised design147; three studies compared CAS 
with CPD versus CAS without CPD,158-160; and three compared CAS with filter CPD versus CAS 
with balloon CPD161-163 three randomised studies, one of which had a 2x2 factorial design148; 
investigated clinical and imaging outcomes of CAS according to different regimens of peri-
interventional platelet-inhibition148, 164 and statin treatment;144, 148 a further study investigated DWI 
lesions in CAS using different catheter techniques (use of 7F or 8F catheter or use of a coaxial 
system with use of a 7F or 8F catheter in conjunction with a 4F or 5F catheter), both with and 
without using CPD.165 Nineteen studies compared DWI lesions and clinical outcomes in CEA 
versus CAS,166-184 only two of which were randomised.176, 184  Details of included studies are 
provided in supplementary table 1. 
Incidence of positive DWI and procedural ischaemic stroke in CAS and CEA 
Data from 85 separate CAS treatment groups reporting on outcomes of 4871 CAS procedures 
were available from eligible single treatment group and multiple treatment group (comparative) 
studies combined. Carotid symptom status was available in 3829 CAS procedures, and 2023 of 
those (53%) were done in symptomatic carotid stenosis. New ischaemic lesions on DWI were 
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found after 1805 procedures (average risk 37%), while procedural ischaemic strokes were 
reported to have occurred in 131 procedures (2.6%; table 1). 
Eligible studies provided data for 34 separate CEA treatment groups including 2099 CEA 
procedures. For 1877 of these CEA procedures carotid symptom status was available, and 1238  
of them (66%) were done in patients with symptomatic carotid stenosis. New DWI lesions were 
detected after 222 procedures (10.8%) and 30 procedures (1.4%) were complicated by procedural 
ischaemic strokes (table 1). 
Correlation between risk of cerebral ischaemia on DWI and risk of procedural ischaemic stroke 
The crude risks of DWI+ and stroke observed in all 119 treatment groups (CEA and CAS 
combined) are displayed in figure 4A. The crude correlation between these risks was 0.29 
(p=0.0014). Figure 2 illustrates why this crude correlation underestimates the magnitude of the 
association between the underlying risks. The correlation between the underlying log odds of 
DWI+ and the log odds of stroke corrected for this underestimation using the bivariate random 
effects logistic regression model was 0.61 (95% CI 0.27 to 0.87; p=0.0012). The slope of this 
relationship was 1.20 (95% CI 0.50 to 2.39), this being an estimate of the change in log odds of 
DWI+ per 1 unit change in the log odds of stroke. Figure 4B converts this estimated linear 
relationship between the two log odds ratios into the non-linear relationship between the estimated 
risks. Within the range of procedural stroke risk of between 2% and 7% reported in previous clinical 
trials of CEA or CAS for symptomatic and asymptomatic carotid stenosis, new ischaemic lesions 
on post-procedural scans can be expected to occur in about ten times this proportion. Figure 4B 
shows that for a particular drug or interventional technique in a future randomised controlled trial 
postulated to reduce procedural stroke risk from 6% to 3% then the predicted reduction in DWI+ 
risk would be from 56% to 35%. For a standard two-arm clinical trial, with 90% statistical power to 
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detect a difference that is statistically significant at the 5% level using a two-sided test, this equates 
to a reduction in sample size from 2004 to 228, almost a 90% reduction. 
Including only CAS treatment groups, the crude correlation between DWI+ and stroke was 0.19 
and the corrected correlation was 0.27 (95% CI -0.19, 0.66], p=0.24). There were too few studies 
done on CEA and too little variance in stroke risk between studies to be able to accurately estimate 
the between study variance in stroke risk (with this actually being estimated as zero). Therefore, 
the corrected correlation between DWI+ and stroke could not be calculated for CEA.  
Comparison of treatment effects on cerebral ischaemia on DWI and procedural ischaemic stroke 
19 eligible studies compared DWI findings and clinical outcomes between CAS and CEA. Across 
these studies, the risk of being DWI+ after CAS was 3.83 times that after CEA (95% 3.17 to 4.63; 
p<0.00001; figure 5) while the risk of ischaemic procedural stroke after CAS was 2.38 times 
(95%CI 1.44 to 3.94; p=0.0007; figure 6) that after CEA.  
 
Discussion 
In our systematic review of the literature, new ischaemic lesions on DWI were present on average 
in 37% of patients following CAS compared to 10.8% of patients after CEA; in contrast, the 
reported risks of procedural ischaemic stroke were only 2.6% and 1.4%, respectively. Across all 
groups of patients treated with CAS or CEA, the risk of a positive DWI scan after treatment 
significantly correlated with the risk of procedural stroke. Among those studies comparing CAS 
versus CEA, summary treatment effects on the occurrence DWI lesions pointed in the same 
direction as summary treatment effects on ischaemic stroke, i.e. the risks of both clinical and 
radiological cerebral ischaemia were increased in CAS compared to CEA. Does the current 
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evidence therefore support the use of DWI as a surrogate outcome measure for procedural safety 
in trials of carotid interventions?  
The statistical methodology involved in validating surrogate markers is complex and 
controversial.185  A set of formal statistical rules for validating surrogate outcome measures has 
been proposed to reduce observation time in prospective trials of progressive diseases.186 These 
rules state among other criteria that the surrogate must predict clinically manifest disease in the 
future and that the full effect of treatment on the clinical outcome must be explained by the effect 
of treatment on the surrogate outcome. It is evident that we cannot use these formal criteria to 
validate DWI lesions as a surrogate outcome measure of procedural stroke in carotid 
interventions: both the potential surrogate – DWI lesions – and the clinical endpoint – procedural 
stroke – are short-term outcome measures characterising risk of procedure; the major advantage 
of DWI as a surrogate outcome is that ischaemic brain lesions are much more common than 
clinically manifest stroke, allowing reductions in the sample size of pilot trials investigating novel 
approaches in reducing treatment risks (e.g. surgical technique, stent design, CPDs and peri-
procedural medication). Hence, we evaluated potential surrogacy of DWI against a set of more 
general rules defined the ICH Harmonised Tripartite Guideline: Statistical Principals for Clinical 
Trials.11 
Is cerebral ischaemia on DWI a biologically plausible surrogate outcome measure for procedural 
ischaemic stroke?  
Stroke is the most common serious adverse event occurring in carotid revascularisation 
procedures. In a meta-analysis of randomised trials comparing CAS versus CEA for symptomatic 
carotid stenosis, 94% of all strokes occurring within 30 days of CAS and 81% of all strokes 
occurring within 30 days of CEA were attributable to ischaemic cerebral infarction and the 
remaining events to intracerebral haemorrhage.187   
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Acute cerebral ischaemia leads to a cascade of events on the biological level, including break-
down of electrolyte transport across the cellular membrane with subsequent shift of water from 
the extracellular to the intracellular space (cytotoxic edema). The reduction in extracellular water 
causes a decrease in random translational motion of water molecules. Diffusion weighted images 
are generated by measuring this random motion of water molecules by the effect of magnetic 
gradients on protons. Areas of reduced water diffusion are shown hyperintense in relation to 
surrounding normal brain tissue. DWI detects brain ischaemia in more than 90% of patients with 
the final clinical diagnosis of acute ischaemic stroke, and sensitivity and inter-rater reliability are 
superior to computer tomography or conventional (T2-weighted or FLAIR) MRI.18, 188, 189 However, 
DWI may also show ischaemic lesions in the absence of a stroke: hyperintense brain lesions on 
DWI may be found in about a third patients with transient ischaemic attacks (TIA).190, 191 
Furthermore, brain ischaemia on DWI without associated focal neurological deficit has been 
shown in patients with carotid stenosis192 and following therapeutic or investigational procedures 
on the heart or the carotid artery13. DWI therefore identifies a spectrum of acute cerebral ischaemia 
encompassing asymptomatic lesions, TIA and stroke. Based on its specificity to image processes 
in the brain directly linked to cellular hypoxia, and its sensitivity in detecting acute cerebral 
ischaemia, the use of DWI as a surrogate outcome measure for procedural ischaemic stroke 
seems biologically plausible. 
Does ischaemia on DWI correlate with procedural stroke during carotid interventions? The result 
of our analysis including all populations treated with CAS or CEA demonstrates a significant 
correlation between the true risk of stroke and the true risk of cerebral ischaemia (p=0.0012). A 
statistically significant association of the potential surrogate and clinical outcome constitutes the 
basis for a use of the surrogate as an endpoint in clinical trials. Our statistical methodology does 
not allow us to fully establish surrogacy, however it does go part of the way towards this since it 
allows the magnitude of the association between the risk of a stroke and the risk of DWI lesions 
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to be estimated, taking account of the fact that imprecision in the estimates of these two risks will 
tend to dilute the magnitude of the underlying association. The fact that the observed correlation 
between the underlying log odds ratio is strong (albeit with a wide 95% confidence interval) is 
encouraging. The steepness of the association, coupled with the fact that the prevalence of DWI 
lesions is much greater than that of stroke illustrates that substantial sample size reductions for 
clinical trials may be possible by switching from a clinically-based stroke outcome to MRI-based 
DWI lesions. Returning to the example given in the introduction, instead of 2000 patients (1000 in 
each treatment group) needed to detect an underlying 3% absolute difference in procedural stroke 
risk, just over 200 patients would be needed to detect the corresponding difference in DWI lesion 
risk. The proof of a significant correlation of a potential surrogate outcome measure and the true 
clinical outcome is crucial but not sufficient by itself to fully validate surrogacy.  
Does the effect of treatment on ischaemic lesions on DWI correspond to the effect of treatment 
on procedural stroke? Despite the corresponding summary treatment effects on DWI lesions and 
procedural stroke in studies comparing CAS versus CEA, there was no clear relationship between 
the relative risks of DWI positivity and stroke across these studies. The observed number of 
strokes was very small in most of these comparative studies and estimated relative risks were 
surrounded by high confidence intervals. Therefore, despite a strong theoretical background 
supporting the use of DWI as a surrogate outcome measure for procedural stroke in carotid 
interventions, and evidence for a correlation of DWI lesions with procedural stroke, the existing 
evidence is insufficient to assess the relationship between the effect of treatment on DWI lesions 
and on procedural stroke. More data from randomised clinical trials of carotid revascularisation 
are required to test this criterion. Apart from comparisons of CAS versus CEA, such randomised 
trials may also compare various surgical or interventional techniques, such as cerebral protection 
devices, access routes, or medication. They need to incorporate serial MR imaging including DWI 
and be of adequate size to detect a sufficient number of clinically manifest strokes. In our 
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experience, a time window of 1-7 days before and 1-3 days after the carotid revascularisation 
procedure for the pre- and post-procedural scan is suitable to detect new ischaemic brain lesions 
caused by the procedure while at the same time allowing for enough flexibility in scheduling the 
scans. 
Summarizing data from several studies does imply limitations, most importantly the heterogeneity 
of the included studies. Firstly, the included studies commonly included both patients with 
symptomatic and asymptomatic carotid stenosis with the proportion of patients having a 
symptomatic stenosis ranging between 0% and 100% within subgroups (symptomatic stenosis 
across studies, 53% of all CAS procedures, and 66% of all CEA procedures). Recently 
symptomatic carotid stenosis may be more prone to embolization and subsequent DWI+ during 
CAS or CEA due to instability of the atherosclerotic plaque. Secondly, the included studies did 
use different time windows for pre- and post-treatment MRI scanning, which may have influenced 
the rate of post-procedural ischaemic brain lesions detected on DWI. Thirdly, definitions of what 
constituted a new ischaemic lesion after treatment differed: some studies purely relied on new 
hyperintense lesions on post-treatment DWI which had not been present before treatment. In other 
studies, a corresponding hypointense signal on ADC maps was additionally required. However, 
very small acute ischaemic lesions appearing hyperintense on DWI may not be identified on ADC 
maps due to limited spatial resolution. Finally, less than half of the included 85 studies clearly 
stated that either clinical assessment for procedural complications was done by an independent 
neurologist or outcome event adjudication was performed; lower reported incidence of procedural 
stroke in the absence of clinical evaluation by a neurologist is a well-known phenomenon. 
However, the average risk of procedural stroke in studies with reported event confirmation by a 
neurologist was only slightly higher than in studies without (2.6% vs 2.1%).  
The importance of DWI lesions occurring during treatment of carotid stenosis may go beyond 
being a surrogate of procedural stroke. In a prospective, population-based study investigating the 
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association of silent brain infarcts and neurocognitive decline, silent brain infarcts were associated 
with a higher risk of dementia and a steeper decline in cognitive function.193 Silent ischaemic brain 
lesions following coronary artery bypass grafting194 and intra-cardiac surgery195 have also been 
associated with cognitive decline. Only a few small studies performed both cognitive testing and 
DWI before and after carotid revascularisation.38, 86, 105, 196 These studies identified few patients 
with post-treatment ischaemia on DWI and were unable to demonstrate or refute a relationship 
between subclinical ischaemia and cognitive decline. An MRI based sub-study within the 
International Carotid Stenting Study investigated multiple aspects of both the occurrence of new 
DWI lesions and ischaemic events in the procedural period after randomised assignment to CAS 
or CEA for symptomatic carotid stenosis.6 After CAS treatment, there was a significantly higher 
rate of recurrent stroke or TIA during follow-up among patients with new ischaemic brain lesions 
on DWI after treatment than among those without new DWI lesions.98  These findings may suggest 
that new DWI lesions after CAS could further serve as a marker to identify patients at higher risk 
for future events.  
Conclusion: Our findings prove a strong correlation between DWI+ and procedural stroke as 
clinical outcome measure in carotid interventions. The results of our analyses therefore strengthen 
the evidence base for the use of DWI+ as a surrogate outcome measure for procedural risk in 
carotid revascularisation. However, despite including a large number of studies with over 6000 
carotid interventions criteria for validation of a surrogate marker are still only partly satisfied. 
Further, randomised studies comparing treatment effects on DWI lesions and clinical stroke are 
needed to fully establish surrogacy. 
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Tables  
 
Table 1:  Average risks of cerebral ischaemia on diffusion-weighted magnetic resonance 
imaging and procedural ischaemic stroke in carotid artery stenting and carotid 
endarterectomy  
 
  
Treatment 
groups 
N 
Included 
procedures 
N 
Symptomatic 
carotid stenosis 
N (%) *** 
DWI+ 
N (%) 
Ischaemic 
Stroke 
N (%) 
Carotid artery stenting * 85 4871 2023/3829 (53) 1805 (37) 131 (2.6) 
Any protection 
device used 
64 3000 1225/2674 (46) 1104 (37) 78 (2.6) 
No protection 
device used  
14 698 490/679 (72) 259 (37.1) 25 (3.6) 
Carotid endarterectomy ** 34 2099 1238/1877 (66) 222 (10.8) 30 (1.4) 
General 
anaesthesia 
25 1418 750/1193 (62.9) 161 (11.4) 19 (1.3) 
Local anaesthesia  5 458 318/433 (73.4) 39 (8.5) 6 (1.3) 
 
Table 1, legend: Data from treatment groups reported in 85 different studies are presented as numbers and 
percentages. CAS, carotid artery stenting; CEA, carotid endarterectomy; DWI+, at least 1 new lesion on 
diffusion weighted imaging after treatment.  
* Including all CAS treatment groups. In 7 studies, patients were treated with or without the use of cerebral 
protection devices but data were not reported separately.  
** Including all CEA treatment groups. In 2 studies, patients were operated under general or local 
anaesthesia but data were not reported separately. Two further studies did not report on the type of used 
anaesthesia .  
*** Carotid symptom status was available in 3829 CAS and 1877 CEA procedures, respectively. 
Percentages of procedures done on symptomatic stenosis of procedures with known symptom status are 
presented.  
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Supplemental methods:  
Using 𝜋𝑠𝑖 and 𝜋𝑑𝑖 to denote the underlying risks of stroke and DWI+ in the ith treatment group and 
Ni, Si and Di to denote the observed numbers of patients, patients suffering a stroke and patients 
classified as DWI+ in that group respectively, the model is specified by the following three 
equations.  
𝑆𝑖~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁𝑖 , 𝜋𝑠𝑖)                                                                     (1) 
𝐷𝑖 − 𝑆𝑖~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁𝑖  − 𝑆𝑖, ((𝜋𝑑𝑖 − 𝜋𝑠𝑖) (1 − 𝜋𝑠𝑖)⁄ ))           (2) 
(
log (𝜋𝑑𝑖 (1 − 𝜋𝑑𝑖)⁄ )
log (𝜋𝑠𝑖 (1 − 𝜋𝑠𝑖)⁄ )
) ~𝑁 ((
𝜇𝑑
𝜇𝑠
) , (
𝜎𝑑
2 𝑟𝜎𝑑𝜎𝑠
𝑟𝜎𝑑𝜎𝑠 𝜎𝑠
2 ))           (3) 
Equation (1) states that the number of strokes in the ith treatment group follows a binomial 
distribution. Equation (2) states that the number of DWI+ cases among those not suffering a stroke 
also follows a binomial distribution whose mean is chosen such that the overall risk of being DWI+ 
in that treatment group is 𝜋𝑑𝑖 (𝜋𝑑𝑖 = 𝜋𝑠𝑖 + (1 − 𝜋𝑠𝑖) × (𝜋𝑑𝑖 − 𝜋𝑠𝑖) (1 − 𝜋𝑠𝑖)⁄ ). Equation (3) states 
that the underlying log odds of the two types of event follow a bivariate normal distribution. This 
model was fitted using PROC NLMIXED in SAS software, version 9.2 (copyright, SAS Institute 
Inc., Cary, NC, USA), with 95% confidence intervals for r (the correlation coefficient for the 
association between the two log odds) constructed using the profile likelihood, and the p-value 
from a likelihood ratio test. Secondary analyses restricted to treatment groups of patients receiving 
CEA or CAS respectively were also attempted. 
To illustrate the effect of imprecision in the two observed risks (DWI+ and stroke) on the 
association between them we performed a simulation (figure 2). Data from 30 treatment groups 
with sample sizes typical of those in our data were simulated using the model defined above with 
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parameters taken to be similar to the parameter estimates from the model using all included 
studies.  
To estimate the change in sample size requirements for a future clinical trial that can be achieved 
by switching the primary outcome from stroke risk to DWI+ risk it is necessary to convert a 
postulated effect on stroke risk to one on DWI+ risk. For example, if it is anticipated that a new 
drug or interventional technique will reduce the risk of procedural stroke from 6% to 3% it is 
necessary to convert each of these anticipated underlying stroke risks to anticipated underlying 
DWI+ risks. The sample size of a phase II trial investigating proof of concept of such an 
intervention could then be calculated to demonstrate the anticipated reduction in DWI+ risk.  
Estimation of the parameters in the bivariate random effects logistic regression model allows such 
conversions to be made because equation (3) implies that there is a linear relationship between 
the underlying log odds of a stroke and the underlying log odds of being DWI+. Specifically, with 
the underlying log odds of being DWI+ as the dependent variable and the underlying log odds of 
a stroke the predictor the line passes through the point (
𝜇𝑑
𝜇𝑠
) and its slope is  𝑟𝜎𝑑/𝜎𝑠.   
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 Supplementary Table 1: 
List of all included studies investigating carotid artery stenting (CAS) for carotid stenosis. CAS treatment groups of comparative studies (CEA vs. CAS) are also included (see 
supplementary table 2 for CEA treatment groups from the same study). The total number of treatment groups in each study is provided (i.e. n=2 if CAS subgroup is part of a comparative 
study (CAS vs. CEA or CAS vs. CAS); N/A: information not available. Outcome data are provided per study including all CAS treatment groups. 
 
Author 
Year of 
first 
publicati
on 
Number of 
treatment 
groups 
included in 
Study, N 
Number of 
CAS 
treatment 
groups 
included  
Number of 
CEA 
treatment 
groups 
included  
CAS 
Procedure
s included 
in study, N 
Symptomati
c carotid 
stenoses, N 
Number of 
reported 
ischaemic 
strokes, N 
(%) 
Relative 
Risk of 
Ischaemic 
Stroke (%) 
Number of 
reported DWI 
+, N (%) 
Relative 
Risk of 
DWI+ (%) 
Use of any 
Protection 
Device (Yes / No 
/ both) 
Loevblad 116 2000 1 1 0 19 N/A 2 10.5 4 21.1 No 
Jaeger 120 2001 1 1 0 20 13 0 0.0 5 25.0 Yes 
Jaeger 117  2002 1 1 0 70 52 1 1.4 22 31.4 No 
Kopp 164  2003 3 3 0 80 13 3 3.8 23 28.8 Both 
Schlueter 121 2003 1 1 0 44 13 1 2.3 10 22.7 Yes 
Flach 166 2004 2 1 1 21 21 1 4.8 9 42.9 Yes 
Garcia-Sanchez 167 2004 2 1 1 10 10 0 0.0 4 40.0 No 
Gauvrit 158 2004 2 2 0 23 12 1 4.3 2 8.7 Both 
Cosottini 159 2005 2 2 0 52 23 1 1.9 16 30.8 Both 
Roh 168  2005 2 1 1 22 18 2 9.1 8 36.4 No 
du Mesnil de 
Rochemont 122 
2006 1 1 0 50 50 0 0.0 19 38.0 Yes 
Iihara 169 2006 2 1 1 92 33 7 7.6 32 34.8 Yes 
Maleux 123 2006 1 1 0 53 17 0 0.0 22 41.5 Yes 
McDonnell 124 2006 1 1 0 110 81 8 7.3 23 20.9 Both 
Pinero 125  2006 1 1 0 162 122 1 0.6 28 17.3 Yes 
Poppert 170  2006 2 1 1 41 18 1 2.4 22 53.7 No 
Rosenkranz 118 2006 1 1 0 27 27 0 0.0 8 29.6 No 
Grunwald 128 2006 1 1 0 10 N/A 0 0.0 4 40.0 Yes 
Schillinger 129 2006 1 1 0 14 0 0 0.0 1 7.1 Yes 
Asakura 126 2006 1 1 0 45 21 0 0.0 20 44.4 Both 
Asakura 127 2006 1 1 0 11 7 0 0.0 2 18.2 Yes 
El-Koussy 161 2007 2 2 0 44 25 2 4.5 13 29.5 Yes 
Faraglia 172  2007 2 1 1 35 11 2 5.7 12 34.3 Yes 
Kim 162 2007 2 2 0 71 47 3 4.2 28 39.4 Yes 
Lacroix 171  2007 2 1 1 61 21 2 3.3 26 42.6 Yes 
Peynirciouglu 119 2007 1 1 0 13 13 0 0.0 1 7.7 No 
Rapp 130 2007 1 1 0 54 29 2 3.7 36 66.7 Yes 
Tedesco 173 2007 2 1 1 34 18 3 8.8 24 70.6 Yes 
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Kastrup 160 2008 2 2 0 243 134 14 5.8 144 59.3 Both 
Palombo 132 2008 1 1 0 98 30 3 3.1 20 20.4 Yes 
Faggioli 134 2008 1 1 0 59 0 0 0.0 34 57.6 Yes 
Schofer 133 2008 1 1 0 59 8 0 0.0 19 32.2 Yes 
Faraglia 137 2008 1 1 0 43 N/A 1 2.3 6 14.0 Yes 
Ghorab 131 2008 1 1 0 50 31 2 4.0 6 12.0 Yes 
Skjelland 174 2009 2 1 1 28 N/A 2 7.1 6 21.4 Yes 
Tedesco 135 2009 1 1 0 20 9 0 0.0 7 35.0 Yes 
Zhou 175 2009 2 1 1 68 N/A 2 2.9 31 45.6 Yes 
Taha 136 2009 1 1 0 98 51 3 3.1 42 42.9 Yes 
Bonati 176  2010 2 1 1 124 124 9 7.3 62 50.0 Both 
Kim 165 2010 1 1 0 32 32 0 0.0 17 53.1 Both 
Palombo 138 2010 1 1 0 111 N/A 4 3.6 33 29.7 Yes 
Rosenkranz 115  2010 1 1 0 147 147 6 4.1 43 29.3 No 
Wasser 177  2010 2 1 1 21 N/A 2 9.5 15 71.4 Both 
Yamada 178 2011 2 1 1 56 34 2 3.6 23 41.1 Yes 
Grunwald 114 2011 1 1 0 194 133 2 1.0 67 34.5 No 
Mitsuoka 183 2011 2 1 1 20 17 0 0 10 50 Yes 
Uchiyama 140 2011 1 1 0 19 19 1 5.3 15 78.9 Yes 
Pinter 139 2011 1 1 0 31 N/A 1 3.2 5 16.1 Yes 
Tulip 141 2012 1 1 0 34 17 1 2.9 17 50.0 Yes 
Felli 179  2012 2 1 1 150 12 3 2.0 51 34.0 Yes 
Leal 142  2012 2 2 0 64 44 0 0.0 15 23.4 Yes 
Capoccia 180 2012 2 1 1 28 0 1 3.6 6 21.4 Yes 
Palombo 143 2012 1 1 0 34 9 0 0.0 8 23.5 Yes 
Akutsu 182 2012 2 1 1 41 19 1 2.4 14 34.1 Yes 
Bijuklic 163 2012 2 2 0 62 25 1 1.6 41 66.1 Yes 
Zhou 181 2012 2 1 1 16 8 0 0.0 8 50.0 Yes 
Takayama 144 2013 2 2 0 61 28 2 3.3 25 41.0 Yes 
Tanemura151 2013 1 1 0 47 23 1 2.1 26 55.3 Yes 
Castro-Afonso150 2013 2 2 0 40 33 0 0 13 32.5 Yes 
Cano 145 2013 2 2 0 60 15 1 1.7 39 65.0 Yes 
Pini 146 2013 1 1 0 20 13 0 0.0 18 90.0 Yes 
Park 147  2013 2 2 0 91 76 1 1.1 36 39.6 Both 
Patti 148 2013 4 (2x2 design) 2 0 156 22 5 6.4 40 33.3 Yes 
Bijuklic 149  2013 1 1 0 728 N/A 8 1.1 241 33.1 Yes 
Gunduz152 2014 1 1 0 52 39 2 3.8 33 63.5 Yes 
Huang153 2014 1 1 0 126 47 4 3.2 33 26.2 Yes 
Kuliha184 2015 2 1 1 77 39 1 1.3 38 49.4 Yes 
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 Supplementary Table 2: 
List of all included studies investigating CEA for carotid stenosis. CEA subgroups of comparative studies (CEA vs. CAS) are included (see supplementary table 1 for corresponding CAS 
subgroups). Number of treatment groups displays the total number of subgroups in each study, i.e. n=2 if CEA subgroup is part of a comparative study (CAS vs. CEA or CEA vs. CEA); N/A: 
information not given 
 
Author 
Year of fist 
publication 
Number of 
treatment 
groups 
included in 
study, N 
Number of 
CEA 
treatment 
groups 
included, 
N 
Number of 
CAS 
treatment 
groups 
included, 
N 
CEA 
Procedures 
included in 
study, N 
Symptoma
tic carotid 
stenoses, 
N 
Number of 
reported 
ischaemic 
strokes, N 
(%) 
Relative 
Risk of 
Ischaemic 
Stroke (%) 
Number of 
reported 
DWI +, N (%) 
Relative 
Risk of 
DWI + (%) 
Type of 
Anaesthesia 
(Local or 
General or 
Both) 
Feiwell 100 2001 1 1 0 25 N/A 0 0 1 4 Local 
Tomczak 101 2001 1 1 0 51 33 2 3.9 6 11.8 N/A 
Mueller 102 2003 1 1 0 33 22 1 3.0 9 27.3 General 
Flach 166 2004 2 1 1 23 23 1 4.3 2 8.7 General 
Garcia-Sanchez 167 2004 2 1 1 10 10 1 10.0 1 10.0 General 
Roh 168 2005 2 1 1 26 19 0 0.0 1 3.8 General 
Iihara 169 2006 2 1 1 139 92 3 2.2 13 9.4 General 
Inoue 103 2006 1 1 0 72 32 1 1.4 3 4.2 General 
Poppert 170 2006 2 1 1 93 44 2 2.2 16 17.2 General 
Faraglia 172 2007 2 1 1 40 8 0 0.0 3 7.5 Both 
Lacroix 171 2007 2 1 1 60 41 2 3.3 7 11.7 General 
Tedesco 173 2007 2 1 1 30 22 0 0.0 1 3.3 General 
Ogasawara 104 2008 1 1 0 163 118 2 1.2 28 17.2 General 
Soinne 105 2008 1 1 0 44 21 0 0.0 2 4.5 General 
Skjelland 174 2009 2 1 1 30 N/A 1 3.3 2 6.7 General 
Zhou 175 2009 2 1 1 100 N/A 2 2.0 12 12.0 General 
Bonati 176 2010 2 1 1 107 107 3 2.8 18 16.8 Both 
Hebb 106 2010 1 1 0 50 18 0 0.0 0 0.0 General 
Wasser 177 2010 2 1 1 28 N/A 0 0.0 1 3.6 General 
Mitsuoka183 2011 2 1 1 25 22 0 0 0 0 N/A 
Yamada 178 2011 2 1 1 25 16 0 0.0 2 8.0 General 
Felli 179 2012 2 1 1 150 138 2 1.3 6 4.0 Local 
Capoccia 180 2012 2 1 1 32 0 0 0.0 1 3.1 Local 
Matsukawa154 2015 1 1 0 36 24 0 0 11 30.6 Yes 
Adhikari155 2016 1 1 0 35 N/A 2 5.7 10 28.6 Yes 
Kuliha156 2016 1 1 0 81 32 0 0 46 56.8 Yes 
Ruffino157 2016 1 1 0 23 14 0 0 7 30.4 Yes 
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Akutsu 182 2012 2 1 1 63 34 0 0.0 11 17.5 General 
Zhou 181 2012 2 1 1 35 19 0 0.0 3 8.6 General 
Oikawa 107 2013 1 1 0 101 101 2 2.0 9 8.9 General 
Yoshida 108 2013 2 1 0 67 36 0 0.0 7 10.4 General 
Cho 109 2013 1 1 0 45 31 0 0.0 4 8.9 Local 
Sfyroeras 110 2013 1 1 0 66 17 0 0.0 5 7.6 General 
Akpinar111 2015 1 1 0 51 28 0 0 8 15.7 General 
Kuliha184 2015 2 1 1 73 48 1 1.4 18 24.7 General 
Bourke112 2016 1 1 0 206 149 4 1.9 27 13.1 Local 
Zhang113 2016 1 1 0 36 25 0 0.0 0 0 General 
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Figure legends:  
 
Figure 1: Diffusion weighted magnetic resonance imaging (DWI) of a patient following stenting of the right carotid artery. 
Multiple hyperintense signals representing acute ischaemic lesions in the territory of the right middle cerebral artery are present. The 
patient did not experience any symptoms. Copyright Department of Radiology, University Hospital Basel. 
 
 
Figure 2: Illustrative example of statistical method using simulated data  
A: Simulated “underlying” (true) log odds of DWI+ (i.e. presence of at least one new DWI brain lesion after treatment) and log odds of 
procedural ischaemic stroke for 30 studies, with regression line. Simulated data was drawn from a bivariate normal distribution with 
means, SDs and correlation similar to those estimated using the actual data by the bivariate random effects logistic regression model. 
This plot therefore represents the ‘corrected’ association between log odds of DWI+ and log odds stroke. 
B: Conversion of simulated “underlying” log odds of DWI+ and stroke to “underlying” risks of DWI+ and stroke for all 30 studies, with 
fitted regression line (risk=exp(log odds)/(exp(log odds)+1). 
C: Simulation of observed risks (hollow circles) by addition of sampling error (random error; green arrows) to both the “underlying” (true) 
risks of DWI+ and stroke (solid circles, as in figure B) through sampling subjects in each of the 30 studies (which have sizes typical of 
the studies included in our analysis). First observed stroke risk was simulated, then it was assumed that everyone who has a stroke is 
DWI+, and finally the number of DWI+ cases amongst those without stroke was simulated. Size of hollow circles for observed risks is 
relative to the number of patients in that study. Smaller studies tend to be subject to greater sampling error (as indicated by typically 
longer arrows). 
D: Simulated observed risks of DWI+ and stroke for 30 studies, with fitted regression line. This plot represents the crude association 
between study-specific DWI+ and stroke risks and demonstrates its underestimation compared with the association of “underlying” 
(true) DWI+ and stroke risks as in figure B (as both factors are subject to sampling error). 
 
 
Figure 3: Flow-chart of selection of retrieved studies for analysis. CAS, carotid artery stenting; CEA, carotid endarterectomy 
 
 
Figure 4: Crude risks of cerebral ischaemia on DWI and procedural ischaemic stroke and fitted association between the 
underlying risks of these outcomes in 119 groups of patients undergoing carotid revascularisation 
A: Observed crude risks of stroke and ischaemia on diffusion weighted imaging (DWI) in all 119 treatment groups. Red triangles 
represent groups of patients treated with carotid endarterectomy and blue dots groups of patients treated with stents. 
B: Fitted regression line relating “underlying” (true) risk of DWI lesions to “underlying” (true) risk of stroke in all included studies. 
Correlation between log odds of DWI lesions and log odds of stroke (coefficient 0.61 [95% CI 0.27, 0.87], p=0.0012). Red lines show 
the magnitude of reduction in risk of DWI lesions that might be observed in a pilot trial expected to reduce the risk of procedural stroke 
from 6% to 3%.  
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Figure 5: Meta-analysis of studies comparing the risk of new ischaemic brain lesions on diffusion weighted imaging after 
carotid artery stenting and carotid endarterectomy.   
Data are numbers of patients with DWI lesions (“events”), total numbers of patients and Mantel-Haenszel fixed-effects risk ratios 
including 95% confidence intervals (CI), with endarterectomy as the reference treatment. Squares on the right represent point estimates 
of risk ratios at trial level, with 95% CI as horizontal bars. The diamond at the bottom represents the summary risk ratio and 95% CI. 
 
 
Figure 6: Meta-analysis of studies comparing the risk of procedural ischaemic stroke between carotid artery stenting and 
carotid endarterectomy.   
The same studies as in Figure 5 are included. Data are numbers of patients with strokes (“events”), total numbers of patients and 
Mantel-Haenszel fixed-effects risk ratios including 95% confidence intervals (CI), with endarterectomy as the reference treatment. 
Squares on the right represent point estimates of risk ratios at trial level, with 95% CI as horizontal bars. The diamond at the bottom 
represents the summary risk ratio and 95% CI. 
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